Evidence map›Paper›PMID 25887919›Full record

ArticleBMC biotechnology2015

Improving the large scale purification of the HIV microbicide, griffithsin.

Joshua L Fuqua, Valentine Wanga, Kenneth E Palmer

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. In Preparation for Outdoor Pharming: Griffithsin Can Be Expressed inFrontiers in bioengineering and biotechnology · 2020
    Article
  11. Low-Cost, Large-Scale Production of the Anti-viral Lectin Griffithsin.Frontiers in bioengineering and biotechnology · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Joshua L FuquaOwensboro Cancer Research Program, 1020 Breckenridge St., Suite 201, Owensboro, KY, 42303, USA. j.fuqua@louisville.edu.
Valentine WangaInstitute for Health Metrics and Evaluation, University of Washington, 2301 5th Ave, Suite 600, Seattle, WA, USA. wangav@uw.edu.
Kenneth E PalmerOwensboro Cancer Research Program, 1020 Breckenridge St., Suite 201, Owensboro, KY, 42303, USA. kenneth.palmer@louisville.edu.
University of Louisville · USInstitute for Health Metrics and Evaluation · US

Funding

Project 3: PREVENT: A first-in-human clinical trial of Griffithsin, an HIV entryU19AI113182 · NIAID · UNIVERSITY OF LOUISVILLE · PI FUQUA, JOSHUA L · 2014 to 2018
$14.8M
Antiviral lectins as microbicidesR01AI076169 · NIAID · UNIVERSITY OF LOUISVILLE · PI PALMER, KENNETH E · 2008 to 2011
$2.3M
NIAID NIH HHS R-01 AI076169NIAID NIH HHS R01 AI076169NIAID NIH HHS U19 AI113182
6 · The paper itself

Abstract

backgroundGriffithsin is a broad spectrum antiviral lectin that inhibits viral entry and maturation processes through binding clusters of oligomannose glycans on viral envelope glycoproteins. An efficient, scaleable manufacturing process for griffithsin active pharmaceutical ingredient (API) is essential for particularly cost-sensitive products such as griffithsin -based topical microbicides for HIV-1 prevention in resource poor settings. Our previously published purification method used ceramic filtration followed by two chromatography steps, resulting in a protein recovery of 30%. Our objective was to develop a scalable purification method for griffithsin expressed in Nicotiana benthamiana plants that would increase yield, reduce production costs, and simplify manufacturing techniques. Considering the future need to transfer griffithsin manufacturing technology to resource poor areas, we chose to focus modifying the purification process, paying particular attention to introducing simple, low-cost, and scalable procedures such as use of temperature, pH, ion concentration, and filtration to enhance product recovery.

resultsWe achieved >99% pure griffithsin API by generating the initial green juice extract in pH 4 buffer, heating the extract to 55°C, incubating overnight with a bentonite MgCl2 mixture, and final purification with Capto™ multimodal chromatography. Griffithsin extracted with this protocol maintains activity comparable to griffithsin purified by the previously published method and we are able to recover a substantially higher yield: 88 ± 5% of griffithsin from the initial extract. The method was scaled to produce gram quantities of griffithsin with high yields, low endotoxin levels, and low purification costs maintained.

conclusionsThe methodology developed to purify griffithsin introduces and develops multiple tools for purification of recombinant proteins from plants at an industrial scale. These tools allow for robust cost-effective production and purification of griffithsin. The methodology can be readily scaled to the bench top or industry and process components can be used for purification of additional proteins based on biophysical characteristics.

Indexed as

Anti-HIV AgentsBentoniteBiotechnologyMagnesium ChlorideNicotianaPlant LectinsRecombinant ProteinsAnti-HIV AgentsBentonitegriffithsin protein, GriffithsiaMagnesium ChloridePlant LectinsRecombinant Proteins

Identifiers

PMID25887919
PMCPMC4349730
OpenAlexW2031869301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.